- Home
- RNA vs SGRY Comparison
RNA vs SGRY Comparison
Compare RNA & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- SGRY
- Stock Information
- Founded
- RNA 2012
- SGRY 2004
- Country
- RNA United States
- SGRY United States
- Employees
- RNA N/A
- SGRY N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- SGRY Hospital/Nursing Management
- Sector
- RNA Health Care
- SGRY Health Care
- Exchange
- RNA Nasdaq
- SGRY Nasdaq
- Market Cap
- RNA 3.4B
- SGRY 2.8B
- IPO Year
- RNA 2020
- SGRY 2015
- Fundamental
- Price
- RNA $30.98
- SGRY $23.61
- Analyst Decision
- RNA Strong Buy
- SGRY Buy
- Analyst Count
- RNA 12
- SGRY 9
- Target Price
- RNA $67.92
- SGRY $34.00
- AVG Volume (30 Days)
- RNA 1.4M
- SGRY 1.1M
- Earning Date
- RNA 05-08-2025
- SGRY 05-12-2025
- Dividend Yield
- RNA N/A
- SGRY N/A
- EPS Growth
- RNA N/A
- SGRY N/A
- EPS
- RNA N/A
- SGRY N/A
- Revenue
- RNA $8,927,000.00
- SGRY $3,172,900,000.00
- Revenue This Year
- RNA N/A
- SGRY $10.72
- Revenue Next Year
- RNA $148.12
- SGRY $9.22
- P/E Ratio
- RNA N/A
- SGRY N/A
- Revenue Growth
- RNA N/A
- SGRY 13.54
- 52 Week Low
- RNA $21.51
- SGRY $19.50
- 52 Week High
- RNA $56.00
- SGRY $33.97
- Technical
- Relative Strength Index (RSI)
- RNA 53.85
- SGRY 57.62
- Support Level
- RNA $30.00
- SGRY $22.78
- Resistance Level
- RNA $32.09
- SGRY $23.28
- Average True Range (ATR)
- RNA 1.79
- SGRY 0.64
- MACD
- RNA 0.13
- SGRY 0.00
- Stochastic Oscillator
- RNA 75.00
- SGRY 70.31
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.